

United States Endometrial Cancer Market By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By Region, Competition Forecast & Opportunities, 2028

<https://marketpublishers.com/r/UD6D4A2D46B9EN.html>

Date: October 2023

Pages: 90

Price: US\$ 3,500.00 (Single User License)

ID: UD6D4A2D46B9EN

Abstracts

In 2022, the United States Endometrial Cancer Market reached a valuation of USD 1.09 billion, and it is poised to experience robust growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.06% through 2028. Endometrial cancer, a prevalent gynecological malignancy, initiates in the endometrium, the lining of the uterus. Recent years have seen significant advancements in the diagnosis, treatment, and research of endometrial cancer, reflecting the increasing need for improved patient outcomes and expanded therapeutic choices.

Several factors contribute to the steady expansion of the United States endometrial cancer market. Foremost among these factors is the escalating global incidence of endometrial cancer, linked to factors such as obesity, hormonal imbalances, and aging populations. This gynecological cancer primarily affects women and stands as one of the most common gynecological cancers on a global scale.

Endometrial cancer typically manifests through symptoms such as post-menopausal bleeding, irregular bleeding between menstrual cycles, pelvic and abdominal pain, unintentional weight loss, and fatigue. Early diagnosis plays a pivotal role in effective endometrial cancer management. Advances in diagnostic technologies, including transvaginal ultrasound, endometrial biopsy, and hysteroscopy, have heightened early

detection rates. Moreover, emerging biomarker-based tests and genetic profiling have improved diagnostic precision, enabling tailored treatment plans for patients.

Treatment strategies for endometrial cancer have evolved significantly, encompassing surgical intervention, radiation therapy, chemotherapy, and hormonal therapy. Minimally invasive surgical techniques like laparoscopy and robotic-assisted surgery are gaining prevalence, offering reduced recovery times and enhanced patient outcomes. In recent years, targeted therapies and immunotherapies have emerged as promising avenues for treating endometrial cancer. Clinical trials exploring novel drug combinations and immunotherapeutic agents have shown potential in improving survival rates among patients with advanced-stage endometrial cancer.

The United States endometrial cancer market has been on a steady upward trajectory due to various factors, including an aging population, rising obesity rates, and shifting lifestyles. The World Cancer Research Fund estimates that endometrial cancer ranks as the sixth most common cancer among women, with projected increases in incidence. Consequently, the demand for advanced diagnostics and therapeutics is experiencing exponential growth. Early detection remains crucial for achieving favorable treatment outcomes, and innovations in diagnostics, including advanced imaging technologies, biomarker tests, and genetic profiling, have significantly enhanced early detection rates. Simultaneously, the therapeutic landscape is evolving, with a shift from conventional treatments to targeted therapies, hormone treatments, and emerging immunotherapies, which are shaping the future of endometrial cancer management.

Key Market Drivers

Rising Cases of Endometrial cancer

Endometrial cancer, a malignancy that affects the lining of the uterus, is on the rise in the United States, and this increase in incidence rates is profoundly impacting the healthcare landscape and the endometrial cancer market. One of the primary factors driving the growth of the endometrial cancer market in the United States is the increasing incidence of the disease. According to the American Cancer Society, approximately 66,200 new cases of uterine cancer, including endometrial cancer, will be diagnosed by 2023. This rise in incidence can be attributed to various factors such as an aging population, hormonal imbalances, obesity, and lifestyle changes. Endometrial cancer is the most common gynecological malignancy in the United States, with a significant portion of cases affecting post-menopausal women. One of the primary

drivers of endometrial cancer is obesity. Obesity is associated with hormonal imbalances, particularly elevated levels of estrogen, which can stimulate the growth of endometrial cells. The United States has experienced a surge in obesity rates, with over 40% of adults classified as obese. As the obesity epidemic continues, the risk of endometrial cancer rises in tandem. Endometrial cancer primarily affects post-menopausal women, and as the population continues to age, there is a natural increase in the number of women at risk for this disease. The aging demographic contributes to the overall upward trend in incidence rates.

Conditions such as polycystic ovary syndrome (PCOS) and prolonged exposure to estrogen without sufficient progesterone can increase the risk of endometrial cancer. These hormonal imbalances are becoming more prevalent, further contributing to the rise in incidence. Certain lifestyle factors, including smoking, poor diet, and sedentary behavior, have been linked to an increased risk of endometrial cancer. The adoption of unhealthy lifestyles by a portion of the population has likely contributed to the higher incidence rates.

Increased Advances in Early Detection

Early detection is pivotal for effective management of endometrial cancer. Technological advancements in diagnostic tools and techniques have significantly improved early detection rates. Transvaginal ultrasound, endometrial biopsy, and hysteroscopy are among the tools that enable healthcare professionals to diagnose endometrial cancer at an earlier, more treatable stage. Additionally, emerging biomarker-based tests and genetic profiling are enhancing precision in diagnosis, driving the demand for advanced diagnostic services. Endometrial cancer, a malignancy originating in the lining of the uterus, poses a significant health challenge in the United States. However, recent advances in early detection technologies and methodologies are reshaping the landscape of endometrial cancer diagnosis and treatment. Transvaginal ultrasound is a non-invasive imaging technique that uses high-frequency sound waves to create images of the uterus.

Recent improvements in ultrasound technology have enhanced the accuracy and resolution of TVUS, making it a valuable tool for detecting abnormalities in the endometrium. TVUS is often used to assess the thickness of the endometrial lining, helping to identify potential issues. Endometrial biopsy is a procedure in which a small tissue sample is taken from the uterine lining for examination under a microscope. Advancements in biopsy techniques, such as the use of hysteroscopy and suction curettage, have made it more precise and minimally invasive. This procedure aids in

diagnosing endometrial cancer and provides critical information about the tumor's stage and grade. Moreover, Molecular biomarkers are specific molecules or genetic markers associated with the presence of endometrial cancer. Recent research has identified various biomarkers, such as PTEN mutations and microsatellite instability, which can be detected through molecular testing. These biomarkers assist in early diagnosis and can guide treatment decisions.

Rising Minimally Invasive Surgical Techniques

Endometrial cancer, a common gynecological malignancy, has seen significant developments in its management over the years, particularly in the realm of surgical techniques. Minimally invasive surgical procedures have emerged as a game-changer, not only improving patient outcomes but also contributing to the growth of the United States' endometrial cancer market. Laparoscopic surgery involves the insertion of a thin, lighted tube with a camera (laparoscope) and other small instruments through small incisions in the abdomen. Surgeons use the laparoscope to visualize and perform the necessary procedures, such as hysterectomy or lymph node dissection.

Laparoscopy offers reduced scarring, shorter hospital stays, quicker recovery times, and lower postoperative pain compared to traditional open surgery. Robotic-assisted surgery combines laparoscopy with the use of robotic arms operated by the surgeon.

The robot provides enhanced precision, dexterity, and 3D visualization, allowing for more intricate and complex procedures. Robotic-assisted surgery offers advantages such as reduced blood loss, shorter hospitalization, and improved cosmetic outcomes. Minimally invasive surgeries offer patients numerous benefits, including reduced postoperative pain, shorter hospital stays, quicker recovery, and improved cosmetic outcomes. Patients often prefer these less invasive approaches, driving demand for these procedures. Healthcare professionals are investing in training and education to become proficient in minimally invasive surgical techniques. Medical institutions and organizations are also offering specialized training programs, further promoting the adoption of these methods. Ambulatory surgery centers (ASCs) are increasingly offering minimally invasive endometrial cancer surgeries. ASCs provide a convenient and cost-effective alternative to traditional hospital settings, attracting patients and contributing to market growth.

Increasing Clinical Trials and Research

Clinical trials and research are instrumental in advancing our understanding of endometrial cancer and in developing new treatment strategies. These efforts involve

rigorous scientific investigation, testing of innovative therapies, and the collection of critical data. Clinical trials provide a platform for testing new treatment modalities, such as targeted therapies, immunotherapies, and combination therapies. Innovative drugs and therapeutic approaches are evaluated for their effectiveness in treating endometrial cancer, often leading to breakthroughs in care. Clinical trials contribute to the expansion of treatment options, providing patients with access to cutting-edge therapies and interventions. This diversity of treatments drives the growth of the pharmaceutical and medical device sectors within the market.

The United States' vibrant clinical trial environment attracts pharmaceutical companies looking to test and commercialize their oncology drugs. This influx of investments bolsters the market's research and development capabilities. Clinical trials and research result in improved patient outcomes, including increased survival rates and enhanced quality of life. Positive patient experiences and outcomes contribute to the market's growth through word-of-mouth referrals. Advances in surgical techniques, including robotic-assisted surgery, drive the demand for advanced medical devices and instruments. Medical device manufacturers invest in research and development to meet this demand.

Key Market Challenges

High Treatment Costs

The cost of treating endometrial cancer can be a significant burden for patients and their families. The rising cost of cancer drugs, surgical procedures, and hospital stays can lead to financial strain and even bankruptcy for some individuals. High treatment costs can also discourage patients from seeking care promptly, which can impact their overall prognosis. The United States Endometrial Cancer Market must find ways to make treatment more affordable and accessible to ensure that patients receive the best care possible without facing financial ruin. As the number of new endometrial cancer cases continues to rise, there is an increased demand for healthcare services. This includes diagnostic tests, surgeries, radiation therapy, chemotherapy, and follow-up care. The surge in cases puts additional pressure on healthcare facilities and providers, potentially leading to longer wait times for diagnosis and treatment.

Surgical interventions, such as hysterectomy or lymph node dissection, are common for endometrial cancer patients. These procedures require hospitalization, operating room expenses, anesthesia, and post-operative care, all of which contribute to the overall cost. Depending on the stage of cancer, radiation therapy may be necessary. This

treatment requires specialized equipment and trained healthcare professionals, adding to the financial burden. Endometrial cancer patients may undergo chemotherapy to target cancer cells. The cost of chemotherapy drugs, administration, and management of side effects can be substantial. Regular follow-up visits, imaging tests, and monitoring are essential for cancer survivors. These ongoing expenses can accumulate over time.

Limited Treatment Options

While there have been notable advancements in the treatment of endometrial cancer, there remains a need for more effective and targeted therapies. Many patients still rely on traditional treatments such as surgery, radiation, and chemotherapy, which can be associated with significant side effects. The development of innovative therapies, such as immunotherapy and targeted therapies, holds promise for improving patient outcomes. However, these treatments are often expensive and may not be accessible to all patients, creating disparities in care.

Unlike some other cancers, endometrial cancer has a limited number of targeted therapies. These therapies are designed to attack specific molecular features of cancer cells, reducing harm to healthy tissues. The scarcity of such treatments limits the ability to personalize care and improve outcomes. Precision medicine, which tailors treatments to the genetic makeup of an individual's cancer, is gaining ground in oncology. However, it remains relatively unexplored in endometrial cancer due to the limited availability of genetic profiling and targeted therapies. Some endometrial cancers develop resistance to standard chemotherapy drugs, making them less effective. This poses a major challenge, as alternative treatment options are limited.

Rising Incidence Rates

One of the most pressing challenges facing the United States Endometrial Cancer Market is the continuous increase in incidence rates. Endometrial cancer is often associated with factors such as obesity, hormonal imbalances, and age, which have been on the rise in recent years. As a result, the number of new cases diagnosed annually has been steadily climbing. This surge in incidence rates puts additional pressure on the healthcare system to provide adequate care and resources for patients. One of the primary drivers of rising endometrial cancer incidence rates is the obesity epidemic in the United States. Obesity is a well-established risk factor for this cancer, as excess body fat can lead to hormonal imbalances, particularly an excess of estrogen. These hormonal imbalances can promote the growth of cancer cells in the endometrial lining.

Hormonal factors, such as early menstruation, late menopause, and certain hormone replacement therapies, can also elevate the risk of developing endometrial cancer. These factors are prevalent in the United States and contribute to the increasing incidence rates. A sedentary lifestyle is another contributor to obesity and, consequently, endometrial cancer risk. Insufficient physical activity is common in the United States, leading to a higher incidence of obesity and related health issues.

Key Market Trends

Advances in Precision Medicine

One of the most significant trends transforming the endometrial cancer landscape is the advent of precision medicine. Genetic profiling and molecular testing are becoming standard practice, allowing oncologists to tailor treatment plans to the unique genetic characteristics of each patient's cancer. This personalized approach improves the effectiveness of therapies and reducing unnecessary side effects.

Genetic profiling has become a standard practice in endometrial cancer diagnosis and treatment. It involves analyzing the DNA and RNA of tumor cells to identify genetic mutations and alterations. This information guides oncologists in selecting targeted therapies that are most likely to be effective for each patient. Identifying biomarkers associated with endometrial cancer is crucial for treatment decisions. Biomarkers provide valuable information about the behavior and characteristics of a tumor, allowing for more precise and individualized treatment plans. Precision medicine enables oncologists to design treatment plans that are specifically tailored to a patient's genetic profile. This approach reduces the need for one-size-fits-all therapies and minimizes unnecessary side effects. Immunotherapy, a groundbreaking treatment approach that harnesses the body's immune system to fight cancer, is being integrated into precision medicine strategies for endometrial cancer. Biomarker testing helps identify patients who are most likely to respond to immunotherapy.

Immunotherapy Breakthroughs

Immunotherapy has emerged as a promising treatment option for endometrial cancer. The development of immunotherapeutic drugs and therapies that harness the body's immune system to target cancer cells has shown remarkable potential in clinical trials. Immunotherapy offers hope for patients with advanced or treatment-resistant endometrial cancer. Immunotherapy, a groundbreaking approach that harnesses the

body's immune system to target cancer cells, is ushering in a new era in the treatment of endometrial cancer in the United States. The United States Endometrial Cancer Market is witnessing significant advancements in immunotherapy, with the potential to revolutionize patient outcomes.

Immunotherapy is highly specific, targeting cancer cells while sparing healthy tissue, reducing side effects, and enhancing the overall quality of life for patients. Some patients experience durable responses to immunotherapy, with the potential for long-term remission and prolonged survival. Immunotherapy can be combined with other treatments, such as chemotherapy and targeted therapies, to enhance its effectiveness and broaden its scope of application. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown remarkable promise in the treatment of advanced or recurrent endometrial cancer. These drugs block inhibitory pathways, allowing the immune system to recognize and attack cancer cells. Identifying specific biomarkers, such as microsatellite instability (MSI) and mismatch repair deficiency (dMMR), helps oncologists determine which patients are most likely to benefit from immunotherapy. This personalized approach maximizes treatment effectiveness.

Segmental Insights

Type of Therapy Insights

In 2022, the Endometrial Cancer Market was dominated by the chemotherapy segment and is predicted to continue expanding over the coming years. This is attributed due to the prevalence of endometrial cancer requiring chemotherapies and the growing advancements in chemotherapy product developments. One of the significant drivers of the chemotherapy segment's growth is the diagnosis of endometrial cancer at advanced stages. In many cases, endometrial cancer is not detected until it has reached an advanced stage, where it may have spread beyond the uterus. Chemotherapy becomes an essential treatment option in these cases to target cancer cells throughout the body.

The integration of chemotherapy into combination therapies is another factor driving growth. Oncologists often combine chemotherapy with other treatment modalities, such as immunotherapy or targeted therapies, to create a more comprehensive and effective treatment plan. This approach improves treatment outcomes and increases the demand for chemotherapy. Chemotherapy remains a primary treatment option for recurrent and metastatic endometrial cancer, where cancer has returned after initial treatment or has spread to other parts of the body. The ability of chemotherapy to target cancer cells systemically makes it a crucial component in managing these challenging cases.

Type of Cancer Insights

In 2022, the Endometrial Cancer Market was dominated by the Endometrial Carcinoma segment and is predicted to continue expanding over the coming years. This is attributed to the rise in incidence of endometrial carcinoma, which has significantly contributed to its dominance. The increasing number of cases underscores the urgent need for effective diagnostic and treatment solutions, driving growth within this segment. Furthermore, advancements in diagnostic techniques and technologies have improved the ability to detect and accurately diagnose endometrial carcinoma. This enhanced diagnostic precision has led to earlier interventions, improving patient outcomes and bolstering the segment's dominance.

Additionally, ongoing research and development efforts focused on endometrial carcinoma have yielded promising treatment options. Innovations in therapies, including targeted treatments and immunotherapies, have shown great potential in effectively managing this form of cancer, further solidifying the segment's position in the market.

Regional Insights

In 2022, the United States Endometrial Cancer Market was dominated by the Mid-West segment and is predicted to continue expanding over the coming years. Firstly, the Mid-West region boasts a significant population, and within that population, there is an increasing awareness of the importance of early detection and treatment of endometrial cancer. This heightened awareness has led to more regular screenings and early interventions, which can significantly impact the market's growth. Moreover, the Mid-West is home to world-class healthcare facilities and research institutions dedicated to cancer care. These institutions conduct cutting-edge research, clinical trials, and treatment innovations, making them focal points for patients seeking the best possible care.

The region's strong healthcare infrastructure, including top-tier hospitals and medical centers, ensures that patients have access to state-of-the-art diagnostic tools and treatment options. This accessibility plays a pivotal role in both early diagnosis and effective management of endometrial cancer.

Key Market Players

Merck KGaA

Eisai Co. Ltd

Novartis AG

Elekta AB

Siemens Healthineers (Varian Medical Systems, Inc.)

GSK plc

Karyopharm Therapeutics

Takeda Pharmaceutical Company Limited

Bristol Myers Squibb

F. Hoffmann-La Roche AG

Report Scope:

In this report, the United States Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

United States Endometrial Cancer Market, By Type of Cancer:

Endometrial Carcinoma

Uterine Sarcomas

United States Endometrial Cancer Market, By Type of Therapy:

Immunotherapy

Radiation Therapy

Chemotherapy

Other Types of Therapies

United States Endometrial Cancer Market, By Diagnosis Method:

Biopsy

Pelvic Ultrasound

Hysteroscopy

CT scan

Other Diagnosis Methods

United States Endometrial Cancer Market, By Region:

North-East

Mid-west

West

South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Endometrial Cancer Market.

Available Customizations:

United States Endometrial Cancer Market report with the given Market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional Market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. UNITED STATES ENDOMETRIAL CANCER MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas)
 - 5.2.2. By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies)
 - 5.2.3. By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other

Diagnosis Methods)

5.2.4. By Company (2022)

5.2.5. By Region (North-East, Mid-west, West, South)

5.3. Market Map

6. NORTH-EAST UNITED STATES ENDOMETRIAL CANCER MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type of Cancer

6.2.2. By Type of Therapy

6.2.3. By Diagnosis Method

7. MID-WEST UNITED STATES ENDOMETRIAL CANCER MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type of Cancer

7.2.2. By Type of Therapy

7.2.3. By Diagnosis Method

8. WEST UNITED STATES ENDOMETRIAL CANCER MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type of Cancer

8.2.2. By Type of Therapy

8.2.3. By Diagnosis Method

9. SOUTH UNITED STATES ENDOMETRIAL CANCER MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type of Cancer

9.2.2. By Type of Therapy

9.2.3. By Diagnosis Method

9.2.4. By Country

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Recent Developments

11.2. Product Launches

11.3. Mergers & Acquisitions

12. PORTER'S FIVE FORCES ANALYSIS

12.1. Competition in the Industry

12.2. Potential of New Entrants

12.3. Power of Suppliers

12.4. Power of Customers

12.5. Threat of Substitute Product

13. COMPETITIVE LANDSCAPE

13.1. Business Overview

13.2. Company Snapshot

13.3. Products & Services

13.4. Financials (In case of listed companies)

13.5. Recent Developments

13.6. SWOT Analysis

13.6.1. Merck KGaA

13.6.2. Eisai Co. Ltd

13.6.3. Novartis AG

13.6.4. Elekta AB

13.6.5. Siemens Healthineers (Varian Medical Systems, Inc.)

13.6.6. GSK plc

13.6.7. Karyopharm Therapeutics

13.6.8. Takeda Pharmaceutical Company Limited

13.6.9. Bristol Myers Squibb

13.6.10. F. Hoffmann-La Roche AG

14. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: United States Endometrial Cancer Market By Type of Cancer (Endometrial Carcinoma, Uterine Sarcomas), By Type of Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies), By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods), By Region, Competition Forecast & Opportunities, 2028

Product link: <https://marketpublishers.com/r/UD6D4A2D46B9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UD6D4A2D46B9EN.html>